Letrozole for Female Infertility
Frontiers in Endocrinology, 2021 Letrozole, an aromatase inhibitor that blocks estrogen synthesis by inhibiting the final step of the estrogen biosynthetic pathway, has been used in the applications of a wide range of infertility settings.
Ai-Min Yang +3 more
doaj +1 more source
Treatment of Girls and Boys with McCune-Albright Syndrome with Precocious Puberty - Update 2017 [PDF]
, 2017 The most common endocrinopathy associated with McCune-Albright Syndrome (MAS) is peripheral precocious puberty (PP) which occurs far more often in girls than in boys.
Eugster, Erica A., Neyman, Anna
core +1 more source
Current evidence supporting "letrozole" for ovulation induction
Journal of Human Reproductive Sciences, 2013 Aromatase inhibitor "letrozole" was first introduced as a potential ovulation induction (OI) drug almost a decade back. Large number of studies has been published using letrozole for OI: In polycystic ovary syndrome (PCOS) women, clomiphene citrate (CC ...
Sujata Kar
doaj +1 more source
Adherence to adjuvant therapy in post-menopausal breast cancer patients: A review [PDF]
, 2011 This is the post-print version of the Article. The official published version can be accessed from the link below - Copyright @ 2012 John Wiley & Sons, IncThis review aimed to address the concept of adherence to adjuvant therapy in post-menopausal women.
Banning, M
core +1 more source
Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer [PDF]
, 2015 Introduction Aromatase inhibitors (AIs) are a vital component of estrogen receptor positive (ER+) breast cancer treatment. De novo and acquired resistance, however, is common.
A Mackay +65 more
core +3 more sources
Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. [PDF]
, 2020 Hundreds of trials are being conducted to evaluate combination of newer targeted drugs as well as immunotherapy. Our aim was to compare efficacy and safety of combination versus single non-cytotoxic anticancer agents. We searched PubMed (01/01/2001 to 03/
Barkauskas, Donald A +4 more
core +1 more source
Anything Rare is Possible: Letrozole Induced Eczematous Skin Eruption [PDF]
Journal of Clinical and Diagnostic Research, 2014 Letrozole is used as first line drug in postmenopausal women with early-stage or advanced hormone-sensitive breast cancer. Letrozole has favourable tolerability profile when administered once daily and significant adverse reactions occur rarely.
Amruta Tripathy +4 more
doaj +1 more source
Effect of letrozole and raloxifene on in vitro human endometrial stromal cells [PDF]
Majallah-i Zanān, Māmā̓ī va Nāzā̓ī-i Īrān, 2020 Introduction: Letrozole and raloxifene are used in female reproductive disease. They have special properties and side-effects. This study was performed with aim to compare the in vitro effects of letrozole and raloxifene on human endometrial stromal ...
Maryam Pourheydar +2 more
doaj +1 more source
Journal of Health Economics and Outcomes Research, 2019 # Objective To evaluate the cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole in post-menopausal women with hormone receptor positive (HR+) and human epidermal growth receptor 2 negative (HER2-) advanced breast cancer from
Gaurav Suri +3 more
doaj +1 more source
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. [PDF]
, 2014 BackgroundIn the BOLERO-2 trial, everolimus (EVE), an inhibitor of mammalian target of rapamycin, demonstrated significant clinical benefit with an acceptable safety profile when administered with exemestane (EXE) in postmenopausal women with hormone ...
Baselga, J +18 more
core +1 more source